MDR1 Mutation Ivermectin Dogs: P-gp Dysfunction, Breed Risks, and Safe Antiparasitic Alternatives 2025
TL;DR / Key Takeaways
- The ABCB1 (MDR1) gene encodes P-glycoprotein (P-gp), an ATP-dependent efflux transporter at the blood-brain barrier; dogs carrying the nt230(del4) frameshift mutation cannot clear certain drugs from the CNS, leading to potentially fatal neurotoxicity.
- Affected herding and sighthound breeds include Rough and Smooth Collies (approximately 65–70% of US dogs carry at least one mutant allele), Australian Shepherds (~50%), and Shetland Sheepdogs (~15–30%), among more than a dozen additional breeds.
- Ivermectin at doses of 0.1–0.2 mg/kg or higher can trigger life-threatening CNS depression in homozygous (mut/mut) dogs; even standard heartworm prevention doses (~6–12 mcg/kg) represent a narrowed safety margin in these animals.
- Isoxazoline ectoparasiticides (afoxolaner, fluralaner, sarolaner, lotilaner) and spinosad are not meaningful P-gp substrates and are preferred antiparasitic options in MDR1-affected dogs.
- Genetic testing for the ABCB1 mutation is commercially available from veterinary diagnostic laboratories and is strongly recommended before administering any P-gp substrate drug to a herding or sighthound breed.
Overview / Summary
For decades, veterinarians observed that Rough Collies and related herding breeds occasionally developed severe, unpredictable neurological crises following routine antiparasitic treatment. The mechanism was clarified in 2001 when researchers at Washington State University linked these reactions to a naturally occurring 4-base-pair deletion in the ABCB1 gene—then widely called the MDR1 gene—encoding P-glycoprotein [1]. This discovery fundamentally reshaped veterinary pharmacogenetics and created the foundation for breed-specific prescribing guidelines that are still being refined in 2025.
The MDR1 mutation ivermectin dogs problem is not an allergy or unpredictable idiosyncratic reaction. It is a pharmacogenetic condition: a predictable, genotype-driven alteration in drug disposition that can transform a normally safe therapeutic dose into a lethal CNS exposure. The mutation is heritable, permanent, and detectable through a simple cheek-swab genetic test—meaning it is entirely preventable as a clinical toxicosis if prescribers and owners are informed.
This article provides a comprehensive, evidence-based overview of ABCB1 mutation biology, its clinical pharmacology with ivermectin and other avermectins, breed-specific prevalence data, risk-stratified dosing guidance, and a practical comparison of safe antiparasitic alternatives. It is intended for veterinary professionals, veterinary pharmacists, and informed owners managing dogs of herding or sighthound ancestry.
Mechanism / Pathophysiology
P-glycoprotein and the Blood-Brain Barrier
P-glycoprotein (P-gp), encoded by the ABCB1 gene (formerly MDR1), is a 170-kDa transmembrane efflux transporter belonging to the ATP-binding cassette (ABC) superfamily. In healthy dogs, P-gp is expressed at high density on the luminal surface of brain capillary endothelial cells, constituting a critical component of the blood-brain barrier (BBB) [1]. Its function is to pump lipophilic xenobiotics—including many drugs—back into the systemic circulation before they can accumulate in CNS parenchyma, functioning as an active pharmacokinetic guardian of the brain.
P-gp is also expressed at the apical surface of intestinal epithelial cells (limiting oral bioavailability of substrates), in hepatocyte canalicular membranes (facilitating biliary excretion), and in renal tubular epithelium. In MDR1-normal dogs, this multi-site expression creates a pharmacokinetic safety net that substantially attenuates CNS exposure to a wide variety of substrates.
The nt230(del4) Frameshift Mutation
The causative variant is a 4-base-pair deletion beginning at nucleotide 230 of the ABCB1 coding sequence, designated nt230(del4) or, in current HGVS nomenclature, ABCB1:c.227_230delATAG. This frameshift generates a premature stop codon, producing a truncated, nonfunctional protein [1]. The mutation is autosomal and incompletely dominant: homozygous mutant dogs (mut/mut) have essentially zero functional P-gp at the BBB, while heterozygous dogs (normal/mut) retain intermediate P-gp expression—often sufficient to maintain partial protection, but with a meaningfully reduced safety margin compared to wild-type animals [2].
The mutation is believed to have arisen from a single ancestral founder event in early herding stock, before modern breed divergence. This explains its concurrent appearance across multiple herding breeds that share a common lineage [3].
How Ivermectin and Avermectins Cause Neurotoxicity
Ivermectin and structurally related avermectins (abamectin, doramectin, eprinomectin, selamectin) act as positive allosteric modulators of glutamate-gated chloride channels (GluCls) found in invertebrate nerve and muscle tissue. These channels are absent in vertebrates, providing the basis for selective antiparasitic efficacy. However, avermectins also potentiate GABA-A receptor activity in vertebrate tissues at sufficiently high concentrations. In healthy mammals, P-gp at the BBB limits avermectin CNS concentrations to sub-toxic levels.
In MDR1-mutant dogs, this barrier is absent or severely compromised. Avermectins entering the systemic circulation are not efficiently pumped out of brain endothelial cells. CNS concentrations rise dramatically, leading to excessive GABA-A receptor activation throughout the brain: chloride channels remain aberrantly open, neuronal membranes hyperpolarize, and global neurotransmission is suppressed. The result is progressive CNS depression—mydriasis, ataxia, hypersalivation, muscle tremors, stupor, and, in severe cases, coma and respiratory arrest.
Loperamide: A Pharmacogenetic Model Drug
Loperamide, an opioid antidiarrheal agent normally excluded from the CNS by P-gp, causes profound CNS opioid toxicity in MDR1 homozygous dogs at standard antidiarrheal doses—an effect not seen in normal dogs [2]. This clinical observation was pivotal in establishing P-gp's role as a CNS-protective efflux pump and illustrates that the problem extends well beyond avermectins to encompass multiple therapeutic drug classes.
Indications / Uses
Licensed Antiparasitic Uses of Ivermectin in Dogs
Ivermectin (Heartgard, Iverhart) is approved for use in dogs primarily as a heartworm (Dirofilaria immitis) prophylactic at oral doses of 6–12 mcg/kg monthly. At this low dose, most MDR1-heterozygous dogs tolerate treatment, though residual risk exists. Ivermectin is also used off-label—under veterinary supervision—for:
- Sarcoptic mange (Sarcoptes scabiei): 200–400 mcg/kg SC or PO, repeated every 1–2 weeks
- Demodicosis (Demodex canis): 300–600 mcg/kg PO daily (pulse or continuous protocols)
- Cheyletiellosis: 200–300 mcg/kg SC or PO
- Ear mites (Otodectes): occasionally used at higher dose ranges
These off-label higher doses—essential for mange and demodicosis treatment—place MDR1-mutant dogs at severe and potentially lethal risk. High-dose ivermectin should never be administered to dogs of uncertain MDR1 genotype from susceptible breeds.
Selamectin, Moxidectin, and Milbemycin Oxime
- Selamectin (Revolution): approved for topical use in dogs for flea, tick, heartworm, ear mite, and mange control. Standard topical doses yield lower peak plasma concentrations than systemic routes and carry a more favorable CNS safety profile in MDR1 dogs, though caution remains warranted.
- Moxidectin (ProHeart 6, ProHeart 12): used in injectable slow-release heartworm prevention. Moxidectin is a P-gp substrate, but slow-release depot formulations keep single-dose systemic concentrations generally below the neurotoxic threshold at licensed doses in most dogs. Risk in homozygous mut/mut animals is still poorly characterized; avoid without veterinary risk-benefit assessment.
- Milbemycin oxime (Interceptor, Sentinel): used for heartworm prevention and intestinal nematode control. Milbemycin has substantially lower affinity for P-gp than ivermectin and is widely regarded as a safer alternative for monthly heartworm prophylaxis in MDR1 dogs at standard doses (0.5–1 mg/kg PO) [2].
- Abamectin: primarily an agricultural acaricide/insecticide, not licensed for companion animals. Inadvertent environmental exposure is an under-recognized hazard in MDR1-affected dogs that access treated agricultural land.
MDR1 Mutation Ivermectin Dogs: Breed Prevalence and Genetic Testing
Affected Breeds and Approximate Allele Frequencies
The following table summarizes breed-specific prevalence data derived from genetic testing laboratory databases and published breed surveys [1, 3]:
| Breed | Approximate % Carrying ≥1 Mutant Allele |
|---|---|
| Rough Collie | ~65–70% |
| Smooth Collie | ~65–70% |
| Australian Shepherd | ~50% |
| Miniature Australian Shepherd | ~50% |
| McNab Shepherd | High frequency (limited published data) |
| Shetland Sheepdog (Sheltie) | ~15–30% |
| Border Collie | ~5% |
| Old English Sheepdog | ~5% |
| Silken Windhound | High frequency (limited published data) |
| Longhaired Whippet | High frequency (limited published data) |
| Mixed-breed dogs with herding ancestry | Variable; testing strongly recommended |
Genetic Testing
Commercial ABCB1 mutation testing is available from veterinary diagnostic laboratories (e.g., Washington State University Veterinary Clinical Pharmacology Lab and others). Testing requires a cheek swab or EDTA blood sample and provides a lifetime determination classified as:
- Normal/normal (wild-type): No mutation; standard P-gp function; full drug dosing range applicable
- Normal/mut (heterozygous): One mutant allele; intermediate risk; avoid high-dose P-gp substrate drugs
- Mut/mut (homozygous): No functional P-gp; high risk; all P-gp substrate drugs require dose avoidance or major reduction
All dogs of susceptible breeds should be genotyped before exposure to any P-gp substrate medication, and results should be permanently documented in the veterinary record.
Dosing / Administration
Dosing for ivermectin and antiparasitic alternatives in dogs must account for MDR1 genotype. The table below stratifies recommendations by genotype and drug indication:
| Genotype / Population | Drug and Indication | Dose | Route and Frequency | Notes |
|---|---|---|---|---|
| Normal/normal (wild-type) | Ivermectin — heartworm prevention | 6–12 mcg/kg | PO monthly | Standard range; commercial tablets |
| Normal/normal (wild-type) | Ivermectin — sarcoptic mange (off-label) | 200–400 mcg/kg | SC or PO; q 1–2 weeks | Veterinary supervision required |
| Normal/mut (heterozygous) | Ivermectin — heartworm prevention | 6–12 mcg/kg | PO monthly | Acceptable; confirm genotype first |
| Normal/mut (heterozygous) | Ivermectin — mange or higher doses | Avoid | — | Reduced safety margin; use alternative |
| Mut/mut (homozygous) | Ivermectin — any dose | Contraindicated | — | Neurotoxicity reported at ≥0.1 mg/kg |
| All genotypes | Milbemycin oxime — heartworm prevention | 0.5–1 mg/kg | PO monthly | Preferred over ivermectin in MDR1 breeds |
| All genotypes | Spinosad (Comfortis) — flea control | 30–60 mg/kg | PO monthly with food | Not a P-gp substrate; safe in MDR1 dogs |
| All genotypes | Afoxolaner (NexGard) — flea/tick | 2.7–6.9 mg/kg (weight-banded) | PO monthly | Isoxazoline; not a P-gp substrate |
| All genotypes | Fluralaner (Bravecto) — flea/tick | 25 mg/kg | PO every 12 weeks | Isoxazoline; extended duration |
| All genotypes | Sarolaner (Simparica) — flea/tick | 2 mg/kg | PO monthly | Isoxazoline; not a P-gp substrate |
| All genotypes | Selamectin (Revolution) — heartworm/ectoparasite | 6–12 mg/kg | Topical monthly | P-gp substrate at high doses; use standard labeled dose only |
All doses represent veterinary-established ranges. Individual dosing must be confirmed by the treating veterinarian based on bodyweight, indication, and genotype.
Key Administration Precautions
Equine ivermectin paste formulations are formulated at concentrations 50- to 100-fold higher than those in canine heartworm tablets. Their use in dogs—by any route, at any dose, in any breed—is inappropriate and dangerous. This is one of the most common causes of severe ivermectin toxicosis seen in veterinary emergency practice. Isoxazolines should be given with food to maximize absorption. Fluralaner's 12-week dosing interval may improve owner compliance compared to monthly oral products.
Adverse Effects / Side Effects / Safety
Clinical Signs of Ivermectin Toxicosis in MDR1 Dogs
Onset of ivermectin toxicosis in homozygous mutant dogs typically occurs within 4–12 hours of oral administration and within 1–2 hours of subcutaneous injection. Clinical progression is dose- and genotype-dependent.
| Adverse Event | Frequency in mut/mut Dogs | Severity | Clinical Action |
|---|---|---|---|
| Mydriasis (dilated pupils) | Very common; earliest sign | Mild–moderate | Immediate veterinary evaluation; do not wait for progression |
| Hypersalivation / vomiting | Common | Mild | Supportive; monitor neurological status closely |
| Ataxia and disorientation | Common | Moderate–severe | Emergency veterinary care required |
| Muscle tremors / fasciculations | Common at doses ≥0.1 mg/kg | Severe | IV diazepam or methocarbamol; ICU monitoring |
| Profound CNS depression / stupor | Common at doses ≥0.2 mg/kg | Life-threatening | Intensive support; consider IV lipid emulsion |
| Coma and respiratory arrest | Dose-dependent | Life-threatening | Mechanical ventilation; ICU; guarded prognosis |
| Prolonged recovery (2–4 weeks) | Common in survivors | Severe | Nursing care, nutritional support, physiotherapy |
| Secondary aspiration pneumonia | Recumbent patients | Severe | Antibiotics; thoracic radiography |
Emergency Management
There is no specific antidote for avermectin toxicosis. Management is entirely supportive:
- Decontamination: In neurologically intact animals presenting within 1–2 hours of ingestion, emesis induction followed by activated charcoal may reduce further absorption. Emesis is contraindicated in obtunded or seizing patients.
- Intravenous lipid emulsion (ILE): A 20% lipid emulsion (Intralipid) administered as an IV bolus (~1.5 mL/kg over 2–3 minutes) followed by a continuous infusion has been used in veterinary toxicology as a lipid-sink strategy to sequester lipophilic avermectins. Case report evidence supports its utility; controlled trials are lacking.
- Seizure and tremor control: Diazepam 0.5–1 mg/kg IV, or phenobarbital for refractory cases.
- Nursing care: Bladder expression, repositioning every 4–6 hours, feeding tube support if comatose, prevention of decubital ulcers.
- Immediate contact: ASPCA Animal Poison Control Center (888-426-4435).
Safety Profile of Alternative Antiparasitics
Isoxazolines (afoxolaner, fluralaner, sarolaner, lotilaner) are not P-gp substrates and do not cause MDR1-related neurotoxicity. However, the FDA has required class-wide label updates warning of rare neurological adverse events (tremors, ataxia, seizures) reported in some dogs receiving isoxazolines—most commonly in animals with pre-existing neurological disease [4]. These events are not MDR1-mediated and are idiosyncratic in nature.
Interactions / Contraindications / Warnings
Drugs That Inhibit P-gp or Are P-gp Substrates
Even in MDR1-normal dogs, concurrent administration of a P-gp inhibitor with an avermectin can partially replicate a functional MDR1-mutant phenotype by saturating or blocking residual P-gp activity.
| Interacting Drug / Class | Mechanism | Clinical Effect | Management |
|---|---|---|---|
| Spinosad (Comfortis) + ivermectin | Spinosad inhibits intestinal and BBB P-gp, reducing ivermectin efflux | Increased CNS ivermectin accumulation; toxicity reported in normal dogs at heartworm-prevention doses | Avoid concurrent use; choose alternative ectoparasiticide |
| Azole antifungals (ketoconazole, itraconazole) | Combined CYP3A4 and P-gp inhibition | Elevated plasma and CNS avermectin concentrations | Avoid combination; if unavoidable, reduce avermectin dose and monitor closely |
| Cyclosporine | Bidirectional P-gp inhibition; both are substrates | Increased CNS and systemic exposure of both drugs | Use lowest effective doses; monitor for renal and neurological toxicity |
| Loperamide (Imodium) | P-gp substrate; CNS excluded in normal dogs | CNS opioid toxicity at antidiarrheal doses in mut/mut dogs | Absolutely contraindicated in MDR1 homozygous dogs |
| Vinca alkaloids (vincristine, vinblastine) | P-gp substrates; reduced biliary and CNS efflux in MDR1 dogs | Excess myelosuppression and potential neurotoxicity in MDR1 dogs receiving chemotherapy | Dose reduction (25–50%) and serial CBC monitoring in affected breeds |
| Doxorubicin | P-gp substrate | Enhanced hematological and cardiac toxicity in MDR1 dogs | Careful dose titration; echocardiographic monitoring |
| Acepromazine | Mechanism unclear; likely CNS accumulation in MDR1 dogs | Prolonged and profound sedation | Reduce dose 25–50%; prefer reversible sedative agents |
Absolute Contraindications
- Ivermectin at any dose above the standard heartworm-prevention range in MDR1 homozygous dogs
- High-dose ivermectin protocols (mange, demodicosis) in MDR1 heterozygous dogs without explicit risk-benefit discussion and owner consent
- Equine-formulated ivermectin paste in any dog regardless of genotype
- Loperamide in any MDR1 homozygous dog
Regulatory Status
The FDA Center for Veterinary Medicine acknowledges breed-specific sensitivities on product labeling for several avermectin-containing products and continues to monitor post-market safety data through its pharmacovigilance program [4]. The spinosad label (Comfortis) explicitly warns against concurrent use with high-dose extralabel ivermectin.
Patient Counseling / Practical Advice
Know your dog's genotype before any new medication. Owners of Rough Collies, Australian Shepherds, Shetland Sheepdogs, or any dog with significant herding ancestry should request ABCB1 genetic testing before their dog receives any new antiparasitic, anticancer, antidiarrheal, or sedative drug. Testing is performed once in a lifetime.
Never use equine or agricultural ivermectin products on dogs. Paste formulations intended for horses are far more concentrated than canine heartworm tablets. Their use has caused deaths even in MDR1-normal dogs; in MDR1-affected breeds, the risk is catastrophic.
Inform every veterinarian and emergency clinic. Document your dog's MDR1 genotype prominently in its health record. Inform every new clinician—including emergency practices, boarding veterinarians, and oncologists—before any sedation, surgery, or chemotherapy. Acepromazine, butorphanol, vincristine, and doxorubicin all require special consideration in MDR1-affected animals.
Recognize early toxicosis signs. Dilated pupils, excessive drooling, stumbling, or unusual sleepiness within hours of receiving a new drug represent a medical emergency. Do not wait to see if signs improve. Contact your veterinarian or the ASPCA Animal Poison Control Center (888-426-4435) immediately.
Safe flea and tick control exists. Afoxolaner (NexGard), fluralaner (Bravecto), sarolaner (Simparica), and lotilaner (Credelio) are isoxazoline-class ectoparasiticides that are not P-gp substrates. They provide excellent, broad-spectrum flea and tick efficacy without MDR1-related neurotoxicity risk and represent the preferred ectoparasiticide class for herding breeds.
Choose milbemycin for heartworm prevention. Milbemycin oxime (Interceptor, Sentinel) has substantially lower P-gp affinity than ivermectin and is widely regarded as the preferred monthly heartworm preventive in MDR1-affected dogs. Discuss this substitution with your veterinarian at the next wellness visit if your dog is currently receiving ivermectin-based products.
Loperamide (Imodium) is dangerous in MDR1 homozygous dogs. This widely available over-the-counter antidiarrheal is absolutely contraindicated in mut/mut dogs. Keep it out of reach and instruct family members and houseguests not to administer it. Request a veterinary-prescribed alternative for gastrointestinal support.
Inform breeders and downstream owners. Because the ABCB1 mutation is heritable, responsible breeding practices include genotyping breeding stock. If your dog is a carrier, inform the breeder and consider reporting results to breed club health registries.
FAQ
Q1: Which dog breeds are affected by MDR1 mutation sensitivity, and do all affected dogs react identically? A1: The mutation is most prevalent in herding breeds: Rough and Smooth Collies (~65–70% carry at least one mutant allele in US populations), Australian Shepherds (~50%), and Shetland Sheepdogs (~15–30%), as well as sighthounds with documented herding admixture [1, 3]. Reaction severity depends on genotype. Homozygous mutant (mut/mut) dogs have essentially no functional P-gp at the BBB and are at the highest risk of toxicosis; heterozygous dogs retain partial P-gp activity and have intermediate risk. Mixed-breed dogs with known herding ancestry should also be tested prior to avermectin or other P-gp substrate drug use.
Q2: Are commercial heartworm tablets containing ivermectin (Heartgard, Iverhart) safe for MDR1 dogs? A2: At the labeled prevention dose of 6–12 mcg/kg monthly, most MDR1-heterozygous dogs and even many homozygous mutant dogs tolerate commercial heartworm tablets without overt toxicity. However, the safety margin is considerably narrower than in wild-type dogs, and veterinary guidance broadly recommends milbemycin oxime (Interceptor) as the preferred alternative in confirmed MDR1-affected dogs [2]. Additionally, concurrent administration of spinosad (Comfortis) with any ivermectin product—even at prevention doses—is explicitly warned against on the spinosad label due to documented drug interaction [4].
Q3: How is ivermectin toxicosis managed in MDR1 dogs? A3: There is no antidote. Management is supportive: decontamination (emesis plus activated charcoal if the dog is neurologically intact and presented early), IV fluid support, diazepam or phenobarbital for tremors and seizures, and intensive nursing care for recumbent patients. Intravenous lipid emulsion (Intralipid 20%) has been used as a lipid-sink strategy based on published case experience and is now routinely discussed in veterinary toxicology protocols. Recovery can extend two to four weeks even with optimal care. The ASPCA Animal Poison Control Center (888-426-4435) provides real-time protocol guidance.
Q4: Are isoxazoline products (NexGard, Bravecto, Simparica) truly safe for MDR1 dogs? A4: Isoxazolines are not meaningful P-gp substrates and carry no MDR1-related neurotoxicity risk. They are the preferred ectoparasiticide class for herding breeds for this reason. The FDA has required class-wide label updates noting rare, idiosyncratic neurological events (tremors, ataxia, seizures) in a small subset of dogs, unrelated to MDR1 genotype and most commonly seen in animals with pre-existing neurological conditions [4]. These events are not predictable from MDR1 status, but dogs with known seizure disorders warrant monitoring with any isoxazoline product.
Q5: Can selective breeding eliminate the MDR1 mutation from affected breeds? A5: In principle, selecting exclusively against mutant-carrying individuals would eventually eliminate the allele, but because the mutation is so prevalent in Rough Collies and Australian Shepherds, this approach would exclude a substantial fraction of each breed's gene pool and risk significant reduction in genetic diversity [3]. Most breed health organizations recommend genotype disclosure and documentation rather than mandatory exclusion of carriers, while encouraging preference for wild-type matings where feasible. Genetic testing of all breeding stock is the minimum standard of responsible practice.
References
[1] Mealey KL, Bentjen SA, Gay JM, Cantor GH. "Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene." Pharmacogenetics. 2001;11(8):727–733. PubMed
[2] Mealey KL. "Therapeutic implications of the MDR-1 gene." J Vet Pharmacol Ther. 2004;27(5):257–264. PubMed
[3] Neff MW, Robertson KR, Wong AK, et al. "Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage." Proc Natl Acad Sci USA. 2004;101(32):11725–11730. PubMed
[4] U.S. Food and Drug Administration, Center for Veterinary Medicine. "Isoxazoline products approved for use in animals — product safety information." FDA
[5] Geyer J, Döring B, Godoy JR, Moritz A, Petzinger E. "Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd." J Vet Pharmacol Ther. 2005;28(1):95–99. PubMed
About the author
Dr. Stanislav Ozarchuk, PharmD, has 15+ years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.
Medical disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.